Current Report · Items 2.02, 8.01 · 8-K

Alto Neuroscience Inc.

ANRONYSEEQUITYCurrent

Results of Operations and Financial Condition · Other Events

Filed Jul 13, 2026Accepted Jul 13, 2026, 7:39 AM EDTCIK 1999480Accession 0001104659-26-082875

Company context

Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Alto’s Precision Psychiatry Platform™ measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to better identify which patients are more likely to respond to Alto product candidates. Alto’s clinical-stage pipeline includes novel drug candidates in bipolar depression, major depressive disorder, treatment resistant depression, schizophrenia, and other mental health conditions. For more information, visit www.altoneuroscience.com or follow Alto on X.

Current securities

ANRONYSE · EQUITY · Current

Recent company filings

Disclosure sections

Items 2.02, 8.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations

Item 2.02. Results of Operations and Financial Condition. The information disclosed under the heading “Cash, Cash Equivalents and Restricted Cash as of June 30, 2026” under Item 8.01 of this Current Report on Form 8-K is incorporated herein by reference and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 8.01Item 8.01 - Other Events

Item 8.01 Other Events. Cash, Cash Equivalents and Restricted Cash as of June 30, 2026 On July 13, 2026, Alto Neuroscience, Inc. (the “Company”) announced that, based upon preliminary estimates and information available to the Company, it estimates that its cash, cash equivalents and restricted cash were approximately $244.2 million as of June 30, 2026. This amount has not been audited, reviewed, or compiled by the Company’s independent registered public accounting firm. The Company’s actual cash, cash equivalents and restricted cash as of June 30, 2026 may differ from these amounts after it completes its comprehensive accounting procedures for the quarter ended June 30, 2026, and any such differences may be material. Pipeline Update The Company intends to accelerate and expand the clinical development of its most advanced program, ALTO-207, including to conduct an additional planned Phase 3 trial of ALTO-207 as monotherapy for the treatment of treatment-resistant depression.

Get the free weekly BCS email.